Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Biogen : Gene Therapy

09/20/2021 | 03:12pm EDT

Biogen Gene Therapy

Junghae Suh, Ph.D., Head of Gene Therapy Accelerator Unit (GTxAU)

R&D Day

September 21, 2021

Forward-looking statements

This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development

programs, clinical trials, and data readouts and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our and our collaboration partners' products and investigational therapies; the anticipated benefits and potential of investments, collaborations, and business development activities; and our future financial and operating results. These forward-looking statements may be accompanied by such words as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "potential," "possible," "prospect," "will," "would," and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development

programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our dependence on sales from our products; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; failure to compete effectively due to significant product competition in the markets for our products; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives;

difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; our dependence on collaborators, joint venture partners, and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks associated with current and potential future healthcare reforms; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media for our business; risks relating to technology failures or breaches; risks relating to management and key personnel changes, including attracting and retaining key personnel; failure to comply with legal and regulatory requirements; the risks of doing business internationally, including currency exchange rate fluctuations; risks relating to investment in our manufacturing capacity; problems with our manufacturing processes; fluctuations in our effective tax rate; the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations, and financial condition; fluctuations in our operating results; risks related to investment in properties; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; risks relating to access to capital and credit markets; risks related to indebtedness; change in control provisions in certain of our collaboration agreements; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission (SEC).

These statements are based on our current beliefs and expectations and speak only as of the date of this presentation. We do not undertake any obligation to publicly update any forward-looking statements.

2

Key messages

We are building Biogen's

Gene Therapy (GTx) R&D Engine to drive innovation and to deliver a continuous pipeline of gene therapies

Gene Therapy Accelerator Unit (GTxAU)

External innovation

Biogen's internal gene

is an important part of

therapy manufacturing

our strategy

facility is underway

3

Building Biogen's gene therapy (GTx) R&D engine with aim of delivering both near- and long-term assets with greater probability of success

Technology Innovation

Bidirectional

Portfolio Delivery

alignment

Focused technology innovation to

Focused system innovation to move

increase probability of success of GTx

GTx programs through pipeline

GTx Pillars

Capsid

Cargo

Vector

Vector

Performance

Production

Tech

Broad CNS, intravitreal,

Regulated/inducible

Routes of

Increase overall yield

muscle-tropic capsids

promoters

administration (ROA)

Increase scalability

Innovation*

Higher potency capsids

Gene editing tools

Immunogenicity, safety

Portfolio

Capsid identification

Cargo optimization

In vitro and in vivo cores

Small-/mid-scale

Structure-activity

Human genetic

Bioanalytics, PK/PD

production

Delivery

Process development

mapping

evidence bioinformatics

modeling

In vivo imaging

Analytical development

*Goals and needs of gene therapy programs

CNS = central nervous system; PK/PD = pharmacokinetics/pharmacodynamics

4

Gene Therapy Accelerator Unit (GTxAU)

Identify and solve key rate-limiting steps in our technologies, capabilities, and drug discovery and development processes to accelerate gene therapy programs through the pipeline.

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Biogen Inc. published this content on 21 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 September 2021 19:11:02 UTC.


ę Publicnow 2021
All news about BIOGEN INC.
10/26Cortexyme's Alzheimer's treatment fails to meet main goals in study
RE
10/26Eli Lilly Alzheimer's Programs Head in Different Directions
DJ
10/26Lilly kicks off application for Alzheimer's drug U.S. approval
RE
10/26Mizuho Securities Cuts Biogen's Price Target to $270 From $300, Citing Aduhelm Sales Es..
MT
10/22BIOGEN : Canaccord Genuity Adjusts Biogen PT to $390 From $423, Maintains Buy Rating
MT
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
DJ
10/22PRESS RELEASE : BB Biotech: Gains realized -2-
DJ
10/21BIOGEN : UBS Adjusts Price Target on Biogen to $406 From $405, Maintains Buy Rating
MT
10/21BIOGEN : Cowen Adjusts Biogen PT to $375 From $450, Maintains Outperform Rating
MT
10/21BIOGEN : JPMorgan Adjusts Biogen's Price Target to $324 From $425, Maintains Neutral Ratin..
MT
More news
Analyst Recommendations on BIOGEN INC.
More recommendations
Financials (USD)
Sales 2021 10 879 M - -
Net income 2021 1 604 M - -
Net Debt 2021 2 311 M - -
P/E ratio 2021 24,3x
Yield 2021 -
Capitalization 38 185 M 38 185 M -
EV / Sales 2021 3,72x
EV / Sales 2022 3,49x
Nbr of Employees 9 100
Free-Float 85,5%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | BIIB | US09062X1037 | MarketScreener
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Last Close Price 259,95 $
Average target price 357,88 $
Spread / Average Target 37,7%
EPS Revisions
Managers and Directors
Michel Vounatsos Chief Executive Officer & Director
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Stelios Papadopoulos Chairman
Alfred W. Sandrock Executive Vice President-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors